Dihydroartemisinin targets VEGFR2 via the NF-κB pathway in endothelial cells to inhibit angiogenesis

Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo

(2012) Chris Zhiyi Zhang et al.   BIOCHEMICAL PHARMACOLOGY

Hypoxia modulates the effect of dihydroartemisinin on endothelial cells

(2011) S. D’Alessandro et al.   BIOCHEMICAL PHARMACOLOGY

Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway

(2011) Shuang-Jia Wang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Antitumor Activity of Artemisinin and Its Derivatives: From a Well-Known Antimalarial Agent to a Potential Anticancer Drug

(2011) Maria P. Crespo-Ortiz et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells

(2010) Jin-Jian Lu et al.   BIOCHEMICAL PHARMACOLOGY

Special features of human retinal angiogenesis

(2010) R F Gariano   EYE

Animal models of choroidal and retinal neovascularization

(2010) Hans E. Grossniklaus et al.   PROGRESS IN RETINAL AND EYE RESEARCH

Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro

(2009) Hui-Jun Zhou et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Constitutive NF- B Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor Growth

(2009) K. Sakamoto et al.   CLINICAL CANCER RESEARCH

I B Kinase-  Regulates Endothelial Cell Motility and Tumor Angiogenesis

(2008) L. M. DeBusk et al.   CANCER RESEARCH

CXCL8/IL8 Stimulates Vascular Endothelial Growth Factor (VEGF) Expression and the Autocrine Activation of VEGFR2 in Endothelial Cells by Activating NFκB through the CBM (Carma3/Bcl10/Malt1) Complex

(2008) Daniel Martin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY